Abbisko Cayman Limited (2256.HK)
HKD 4.46
(-3.67%)
HKD 4.46
(-3.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -511.07 Million CNY | 12.74% |
| 2022 | -492.92 Million CNY | 72.84% |
| 2021 | -1.81 Billion CNY | -156.9% |
| 2020 | -706.46 Million CNY | -426.69% |
| 2019 | -134.13 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 120.95 Million CNY | 0.0% |
| 2024 Q1 | 120.95 Million CNY | 186.47% |
| 2023 Q4 | -139.87 Million CNY | 0.0% |
| 2023 FY | -430.11 Million CNY | 12.74% |
| 2023 Q3 | -139.87 Million HKD | -20.94% |
| 2023 Q2 | -115.65 Million CNY | 0.0% |
| 2023 Q1 | -115.65 Million CNY | 18.07% |
| 2022 Q3 | -141.16 Million CNY | -31.41% |
| 2022 Q2 | -107.42 Million CNY | 0.0% |
| 2022 FY | -492.92 Million CNY | 72.84% |
| 2022 Q4 | -141.16 Million CNY | 0.0% |
| 2022 Q1 | -107.42 Million CNY | -3.35% |
| 2021 Q1 | -123.48 Million CNY | 0.0% |
| 2021 Q3 | -103.94 Million CNY | 59.96% |
| 2021 FY | -1.81 Billion CNY | -156.9% |
| 2021 Q4 | -103.94 Million CNY | 0.0% |
| 2021 Q2 | -259.57 Million CNY | -110.21% |
| 2020 Q1 | -56.37 Million CNY | 0.0% |
| 2020 FY | -706.46 Million CNY | -426.69% |
| 2019 FY | -134.13 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 854.157% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 156.916% |